NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01815242,Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer,https://clinicaltrials.gov/study/NCT01815242,ADAPT,COMPLETED,The trial will evaluate the optimal treatment with nab-paclitaxel in combination with either carboplatin or gemcitabine for patients with triple negative breast cancer.,NO,Breast Cancer,DRUG: nab-Paclitaxel|DRUG: Gemcitabine|DRUG: Carboplatin,"Comparison: pCR in nab-paclitaxel/carboplatin vs. nab-paclitaxel/gemcitabine, pCR will be measured after 12 weeks of randomized treatment., After 12 weeks of therapy|Comparison: pCR in responders vs. non-responders, pCR will be measured after 12 weeks of randomized treatment., After 12 weeks of therapy",,,West German Study Group,Celgene,FEMALE,"ADULT, OLDER_ADULT",PHASE2,336,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,WSG-AM06 / ADAPT TN,2013-06,2015-03,2025-01-15,2013-03-21,,2025-02-27,"Ev. Krankenhaus Bethesda Brustzentrum Niederrhein, MÃ¶nchengladbach, Germany, Moenchengladbach, 41061, Germany",
